Risk-adapted stereotactic ablative radiotherapy for central and ultra-central lung tumours.

CONCLUSIONS: SABR for central and ultra-central tumours is associated with good OS, DFS and LC rates, with 7.3% grade 3-5 toxicities. Central tumours had a better prognosis in our cohort.
PMID: 31005213 [PubMed - in process]

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - April 23, 2019 Category: Radiology Authors: Lenglet A, Campeau MP, Mathieu D, Bahig H, Lambert L, Vu T, Roberge D, Bilodeau L, Filion E Tags: Radiother Oncol Source Type: research